PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29530932-3	2018	Erlotinib resistance due to acquired MTOR mutation was functionally evaluated by in vivo and in vitro studies.Results: In 200 EGFR-mutant pretreatment samples, the most frequent concurrent alterations were mutations in TP53, PIK3CA, CTNNB1, and RB1 and focal amplifications in EGFR, TTF1, MDM2, CDK4, and FOXA1 Shorter time to progression on EGFR TKI was associated with amplification of ERBB2 (HR = 2.4, P = 0.015) or MET (HR = 3.7, P = 0.019), or mutation in TP53 (HR = 1.7, P = 0.006).	Erlotinib Hydrochloride	0-9	tumor protein p53	Homo sapiens	219-223	
32622356-6	2020	After biopsy confirmation, patient was initially started on gemcitabine and oxaliplatin combination followed by gene sequencing, which showed Tp53 (exon 7-c.713 G > A and exon 5-c.376-2A > G) and EGFR (exon 20-T790M) mutation, and erlotinib was added to chemotherapy, after 6 cycles of chemotherapy patient showed a 90% partial radiological response as per RECIST criteria.	Erlotinib Hydrochloride	231-240	tumor protein p53	Homo sapiens	142-146	
30296375-6	2018	The synergistic effect between erlotinib-targeted therapy and photodynamic therapy significantly up-regulates cancer suppressor p53 and inhibits Survivin, which results in more apoptosis and cell cycle arrest.	Erlotinib Hydrochloride	31-40	tumor protein p53	Homo sapiens	128-131	
29530932-3	2018	Erlotinib resistance due to acquired MTOR mutation was functionally evaluated by in vivo and in vitro studies.Results: In 200 EGFR-mutant pretreatment samples, the most frequent concurrent alterations were mutations in TP53, PIK3CA, CTNNB1, and RB1 and focal amplifications in EGFR, TTF1, MDM2, CDK4, and FOXA1 Shorter time to progression on EGFR TKI was associated with amplification of ERBB2 (HR = 2.4, P = 0.015) or MET (HR = 3.7, P = 0.019), or mutation in TP53 (HR = 1.7, P = 0.006).	Erlotinib Hydrochloride	0-9	tumor protein p53	Homo sapiens	461-465	
25164437-10	2014	CONCLUSION: pERK expression may have an impact on OS in erlotinib-treated patients with advanced pancreatic cancer; p53 should be further investigated for its potential role as a predictive marker for PFS and skin rash.	Erlotinib Hydrochloride	56-65	tumor protein p53	Homo sapiens	116-119	
23769318-10	2013	Erlotinib treatment at clinically relevant concentrations induced autophagy (increased LC3II expression, Atg-5/Atg12 conjugation, formation of AVO and p62 degradation) in sensitive NSCLC cell lines, via p53 nuclear translocation, AMPK activation and mTOR suppression.	Erlotinib Hydrochloride	0-9	tumor protein p53	Homo sapiens	203-206	
23856246-5	2013	Furthermore, we identify pharmacogenomic correlations between specific variants in genes such as TP53, BRAF, ERBBs, and ATAD5 and anticancer agents such as nutlin, vemurafenib, erlotinib, and bleomycin showing one of many ways the data could be used to validate and generate novel hypotheses for further investigation.	Erlotinib Hydrochloride	177-186	tumor protein p53	Homo sapiens	97-101	
21109480-8	2011	In combination therapy, p53RA small molecules enhanced the anti-tumor activity of cisplatin, 5-fluorouracil, paclitaxel, and erlotinib against HNSCC cells.	Erlotinib Hydrochloride	125-134	tumor protein p53	Homo sapiens	24-27	
15035290-11	2004	The OSI-774 induced greater (p53-independent) apoptosis in more malignant GBM phenotypes and may be a promising therapeutic agent against secondary GBM.	Erlotinib Hydrochloride	4-11	tumor protein p53	Homo sapiens	29-32	
27165055-8	2016	Keratinocytes treated with erlotinib in vitro showed a significant down-modulation of hyaluronan synthases (HAS2 and HAS3), whereas senescence-associated genes (p21, p53, IL-6, maspin) were upregulated, along with a G1 cell cycle arrest and stronger SA beta-Gal activity.	Erlotinib Hydrochloride	27-36	tumor protein p53	Homo sapiens	166-169	
25714397-5	2015	In this study, we examine the ability of 2 tumor suppressor miRNAs, let-7b and miR-34a to sensitize KRAS;TP53 mutant non-small cell lung cancer cells to the action of erlotinib.	Erlotinib Hydrochloride	167-176	tumor protein p53	Homo sapiens	105-109